Nectar Lifescience Ltd
16 Nov 2026 12:00 AM
Nectar Lifescience Ltd consolidated sales down remained flat on year in Q2FY2027,
Nectar Lifescience Ltd`s net profit stood at Rs 2.72 crore in Q2FY2027 compared to a net loss of Rs 176.01 crore in Q2FY26. The revenue from operations remained flat to Rs 0.01 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.76 lakh crore, gaining 6.97%. It has slipped by 0.66% over last one week and moved up slightly by 6.26% in last one month while the market capitalization of Nectar Lifescience Ltd has improved by 5.82% and 0.66% in the same period respectively.
Profit before tax (PBT) of Nectar Lifescience Ltd stood at Rs 6.43 crore in Q2 FY27, nosediving by 103.66% year-on-year, and plunging by 126.46% quarter-on-quarter. EBITDA came in at Rs 21 crore, crashing by 4088.46% YoY and tumbling by 31.30% sequentially.
Total expenses plunged by 75.56% to Rs 6.8 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 0.89 crore, tanking by 16.04% YoY.
For FY26, revenue from operations tumbled 100% , while net profit witnessed a sharp fall of 8292.86% to Rs 57.35 crore, compared to previous FY. EBITDA saw a sharp decline of 329% to Rs 65.97 crore, and PBT collapsed by 8313.08% to Rs 87.88 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 348.72 crore in FY26, as against Rs 169.44 crore in FY25.
Nectar Lifescience Ltd nosedived by 32.60% in last one year, underperforming the benchmark BSE Sensex which has eased by 3.42% during the same period.
Nectar Lifescience Ltd
14 Nov 2026 12:00 AM
Nectar Lifescience Ltd consolidated sales down remained flat on year in Q2FY2027,
Nectar Lifescience Ltd share price ticked higher by 2.39% to Rs 10.73 after the company`s net profit tanked by 117.66% to Rs 2.72 crore, while revenue from operations remained flat to Rs 0.01 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 6.82%. It has improved by 2.52% over last one week and crept higher by 5.98% in last one month while the market capitalization of Nectar Lifescience Ltd has marginally improved by 5.72% and 4.79% in the same period respectively.
Profit before tax (PBT) of Nectar Lifescience Ltd stood at Rs 6.43 crore in Q2 FY27, tanking 103.66% year-on-year, and crashing by 126.46% quarter-on-quarter. EBITDA came in at Rs 21 crore, tumbling by 4088.46% YoY and plunging by 31.30% sequentially.
Total expenses tumbled by 75.56% to Rs 6.8 crore in Q2FY27 over Q2FY26. During the quarter, employee benefits expense was at Rs 0.89 crore, collapsing by 16.04% YoY.
For FY26, revenue from operations sank 100% , while net profit plunged by 8292.86% to Rs 57.35 crore, compared to previous FY. EBITDA saw a sharp decline of 329% to Rs 65.97 crore, and PBT collapsed by 8313.08% to Rs 87.88 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 348.72 crore in FY26, as against Rs 169.44 crore in FY25.
Nectar Lifescience Ltd nosedived by 32.60% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.42% during the same period.
Nectar Lifescience Ltd
06 Nov 2026 12:00 AM
Nectar Lifesciences schedules board meeting to review quarterly financial results,
Nectar Lifesciences Ltd. will hold a board meeting on November 14, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026, according to a regulatory filing with the National Stock Exchange of India Limited and BSE Limited.
Nectar Lifescience Ltd
06 Oct 2026 12:00 AM
Nectar Lifesciences confirms regulatory compliance with filings to Indian stock exchanges,
Nectar Lifesciences Limited submitted a certificate to the National Stock Exchange of India Limited and BSE Limited on October 6, 2026, confirming compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, and received from Kfin Technologies Limited, the company’s registrar and share transfer agent, for the quarter ended September 30, 2026.
Nectar Lifescience Ltd
24 Sep 2026 12:00 AM
Nectar Lifesciences closes trading window for insiders ahead of September 2026 results,
Nectar Lifesciences Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for dealing in securities of the company will be closed for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of financial results for the period ended September 30, 2026, in accordance with the company’s code of conduct as per SEBI regulations.
Subscribe for our
newsletter
newsletter
HSL Mobile App